Victory Capital Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.07M | Buy |
28,834
+1,412
| +5% | +$45.6K | ﹤0.01% | 1874 |
|
|
2026
Q1 | $870K | Sell |
27,422
-7
| -0% | -$191 | ﹤0.01% | 1892 |
|
|
2025
Q4 | $745K | Buy |
27,429
+39
| +0.1% | +$1.03K | ﹤0.01% | 1942 |
|
|
2025
Q3 | $709K | Sell |
27,390
-260
| -0.9% | -$6.03K | ﹤0.01% | 1971 |
|
|
2025
Q2 | $563K | Buy |
+27,650
| New | +$538K | ﹤0.01% | 2038 |
|
|
2025
Q1 | – | Sell |
-8,003
| Closed | -$202K | – | 2484 |
|
|
2024
Q4 | $202K | Sell |
8,003
-147
| -2% | -$3.99K | ﹤0.01% | 2233 |
|
|
2024
Q3 | $277K | Sell |
8,150
-172
| -2% | -$6.55K | ﹤0.01% | 2154 |
|
|
2024
Q2 | $308K | Buy |
8,322
+87
| +1% | +$3.28K | ﹤0.01% | 2093 |
|
|
2024
Q1 | $346K | Buy |
8,235
+983
| +14% | +$40.4K | ﹤0.01% | 2077 |
|
|
2023
Q4 | $288K | Buy |
+7,252
| New | +$213K | ﹤0.01% | 2139 |
|
|
2023
Q1 | – | Sell |
-5,096
| Closed | -$227K | – | 2608 |
|
|
2022
Q4 | $227K | Sell |
5,096
-6,673
| -57% | -$238K | ﹤0.01% | 2239 |
|
|
2022
Q3 | $331K | Sell |
11,769
-6,918
| -37% | -$212K | ﹤0.01% | 2210 |
|
|
2022
Q2 | $504K | Buy |
18,687
+1,263
| +7% | +$36.7K | ﹤0.01% | 2050 |
|
|
2022
Q1 | $532K | Buy |
17,424
+1,935
| +12% | +$61.9K | ﹤0.01% | 2103 |
|
|
2021
Q4 | $598K | Sell |
15,489
-4,188
| -21% | -$183K | ﹤0.01% | 2063 |
|
|
2021
Q3 | $1.06M | Sell |
19,677
-3,456
| -15% | -$162K | ﹤0.01% | 1839 |
|
|
2021
Q2 | $774K | Sell |
23,133
-3,632
| -14% | -$99.7K | ﹤0.01% | 1984 |
|
|
2021
Q1 | $551K | Buy |
26,765
+10,012
| +60% | +$230K | ﹤0.01% | 2160 |
|
|
2020
Q4 | $294K | Buy |
+16,753
| New | +$302K | ﹤0.01% | 2287 |
|
|
2020
Q2 | – | Sell |
-2,200
| Closed | -$4K | – | 2657 |
|
|
2020
Q1 | $4K | Buy |
+2,200
| New | +$4.97K | ﹤0.01% | 3335 |
|
|
2019
Q4 | – | Sell |
-1,796
| Closed | -$4K | – | 2755 |
|
|
2019
Q3 | $4K | Buy |
+1,796
| New | +$4.16K | ﹤0.01% | 3496 |
|
|
2017
Q2 | – | Sell |
-103
| Closed | -$6K | – | 1812 |
|
|
2017
Q1 | $6K | Hold |
103
| – | – | ﹤0.01% | 1797 |
|
|
2016
Q4 | $5K | Buy |
103
+6
| +6% | +$341 | ﹤0.01% | 1785 |
|
|
2016
Q3 | $6K | Buy |
97
+6
| +7% | +$374 | ﹤0.01% | 1770 |
|
|
2016
Q2 | $6K | Buy |
91
+2
| +2% | +$127 | ﹤0.01% | 1627 |
|
|
2016
Q1 | $5K | Buy |
89
+7
| +9% | +$788 | ﹤0.01% | 1653 |
|
|
2015
Q4 | $19K | Buy |
82
+4
| +5% | +$872 | ﹤0.01% | 1650 |
|
|
2015
Q3 | $12K | Buy |
78
+7
| +10% | +$1.98K | ﹤0.01% | 1601 |
|
|
2015
Q2 | $27K | Buy |
+71
| New | +$28.2K | ﹤0.01% | 1576 |
|
Other funds holding CLDX
KCM
DTC
LGM
Victory Capital Management's CLDX Position: Q2 2026 in Review
Victory Capital Management increased its Celldex Therapeutics (CLDX) stake by 5.1% in Q2 2026, buying an estimated $45.6K and bringing the position to 28,834 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1874.
Victory Capital Management first reported a position in CLDX in Q2 2015 and has held it in 29 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.
- Victory Capital Management held 28,834 shares of Celldex Therapeutics worth $1.07M as of Q2 2026.
- Victory Capital Management bought 1,412 Celldex Therapeutics shares in Q2 2026, an estimated $45.6K.
- Celldex Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1874 holding.
- Victory Capital Management first reported a position in Celldex Therapeutics in Q2 2015 and has held it in 29 quarters since.
- 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.
Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.